Alimta approved in US for first-line use in lung cancer
This article was originally published in Scrip
Executive Summary
Lilly's chemotherapy drug Alimta (pemetrexed) has secured its biggest approval yet in the US, for the first-line treatment of locally-advanced and metastatic non-squamous non-small cell lung cancer (NSCLC).